Through the all-cash deal, St. Jude will divest its Angio-Seal and Femoseal vascular closure products, while Abbott will sell the Vado Steerable Sheath — a device used for navigation during cardiac ablation procedures — to Terumo, according to the companies.
The deal is subject to Abbott’s successful acquisition of St. Jude, which it hopes to achieve by the end of 2016, among other conditions, according to the report.
Abbott, which has been divesting products to focus on cardiovascular devices and diagnostics business, sold its medical optics unit to New Brunswick, N.J.-based Johnson & Johnson for $4.3 billion in September, according to the report.
More articles on supply chain:
Medical technology sales to hit $500B within 5 years: 4 takeaways
4 thoughts Americans have on drone deliveries
How one Bernie Sanders tweet cost this drug company $387M
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.